Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Risk Factors for Rescue Therapy in Crohn’s Patients Maintained on Infliximab After Withdrawal of the Immunomodulator: A Long-Term Follow-Up

Published:2017-10-06 Issue:11 Volume:62 Page:3131-3137
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Dig Dis Sci

Author:

Fischer Monika,Campbell Sarah C.,Calley Cynthia S. J.,Helper Debra J.,Chiorean Michael V.,Fadda Hala M.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/article/10.1007/s10620-017-4771-z/fulltext.html

Reference23 articles.

1. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489–1499.

2. Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.

3. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995;123:132–142.

4. Terdiman JP, Gruss CB, Heidelbaugh JJ, Sultan S, Falck-Ytter YT. American Gastroenterological Association Institute guideline on the use of thiopurines, methotrexate, and anti-TNF-alpha biologic drugs for the induction and maintenance of remission in inflammatory Crohn’s disease. Gastroenterology. 2013;145:1459–1463.

5. Gomollon F, Dignass A, Annese V, et al. European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohn’s Colitis. 2017;11:3–25.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reply;Clinical Gastroenterology and Hepatology;2023-02

2. Immunomodulator Withdrawal From Anti-TNF Therapy Is Not Associated With Loss of Response in Inflammatory Bowel Disease;Clinical Gastroenterology and Hepatology;2022-11

3. Evidence-based efficacy of methotrexate in adult Crohn’s disease in different intestinal and extraintestinal indications;Therapeutic Advances in Gastroenterology;2022-01

4. A User’s Guide to De-escalating Immunomodulator and Biologic Therapy in Inflammatory Bowel Disease;Clinical Gastroenterology and Hepatology;2020-05

5. De-escalation of immunomodulator and biological therapy in inflammatory bowel disease;The Lancet Gastroenterology & Hepatology;2020-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3